Skyrizi* (Risankizumab-Rzaa) — Medicare Part D spending
Abbvie US LLC* · Rank #167 by total Part D spend · CMS data year 2023
Medicare Part D spent $289,245,101 on Skyrizi* (Risankizumab-Rzaa) in 2023, the #167 drug by total Part D spending out of 3,598 drugs. That worked out to about $18,680.38 per dosage unit, $19,611 per claim and $60,184 per beneficiary, across 14,749 claims for 4,806 beneficiaries. Average spending per dosage unit rose +0.7% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Skyrizi* (Risankizumab-Rzaa) spending at a glance (2023)
| Metric | Skyrizi* (Risankizumab-Rzaa) |
|---|---|
| Total Part D spending (2023) | $289,245,101 |
| Total spending (2022) | $251,093,665 |
| Year-over-year change in total spending | +15.2% |
| Average spending per dosage unit (2023) | $18,680.38 |
| Change in spend per dosage unit (YoY) | +0.7% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +3.7% |
| Average spending per claim (2023) | $19,611 |
| Average spending per beneficiary (2023) | $60,184 |
| Total claims (2023) | 14,749 |
| Beneficiaries (2023) | 4,806 |
| Total dosage units (2023) | 27,777 |
| Manufacturer(s) | Abbvie US LLC* |
| National rank by total spend (of 3,598 drugs) | #167 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $251,093,665 | $289,245,101 | +15.2% |
| Avg spend per dosage unit | $18,551.61 | $18,680.38 | +0.7% |
| Avg spend per claim | $18,841 | $19,611 | — |
| Avg spend per beneficiary | $58,557 | $60,184 | — |
| Total claims | 13,327 | 14,749 | — |
| Beneficiaries | 4,288 | 4,806 | — |
How Skyrizi* compares with nearby drugs
Drugs with total Part D spending closest to Skyrizi* (Risankizumab-Rzaa):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Skyrizi* (Risankizumab-Rzaa) (this drug, #167) | $289,245,101 | $18,680.38 | +0.7% |
| Radicava Ors (Edaravone) (#165) | $293,678,844 | $271.04 | +2.1% |
| Ezetimibe (#166) | $290,177,168 | $0.57 | -29.0% |
| Pregabalin (#168) | $287,950,539 | $0.51 | -5.1% |
| Levemir (Insulin Detemir) (#169) | $287,253,250 | $32.63 | +0.7% |
| Bydureon Bcise (Exenatide Microspheres) (#170) | $284,056,759 | $244.15 | +3.1% |
Frequently asked questions
How much does Medicare Part D spend on Skyrizi*?
Medicare Part D spent $289,245,101 on Skyrizi* (Risankizumab-Rzaa) in 2023 (the latest CMS data year), across 14,749 claims for 4,806 beneficiaries. That ranks #167 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Skyrizi*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Skyrizi* (Risankizumab-Rzaa) was $18,680.38. Compared with 2022 it rose +0.7%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Skyrizi*?
CMS attributes Skyrizi* (Risankizumab-Rzaa) to Abbvie US LLC* in the 2023 Part D spending file. Average spending per claim was $19,611 and per beneficiary $60,184.
Is the Skyrizi* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20